Last reviewed · How we verify

Sinotau Pharmaceutical Group — Portfolio Competitive Intelligence Brief

Sinotau Pharmaceutical Group pipeline: 0 marketed, 0 filed, 3 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 3 Phase 3 1 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Lutetium[177Lu] Oxodotreotide Injection Lutetium[177Lu] Oxodotreotide Injection phase 3 Radiolabeled peptide; peptide receptor radionuclide therapy (PRRT) Somatostatin receptor 2 (SSTR2) Oncology
XTR004 XTR004 phase 3 SGLT2 inhibitor SGLT2 Diabetes
XTR006 XTR006 phase 3 SGLT2 inhibitor SGLT2 Diabetes

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. ADvantage Therapeutics · 1 shared drug class
  2. AJU Pharm Co., Ltd. · 1 shared drug class
  3. AO GENERIUM · 1 shared drug class
  4. Abbott · 1 shared drug class
  5. AceLink Therapeutics, Inc. · 1 shared drug class
  6. Ache Laboratorios Farmaceuticos S.A. · 1 shared drug class
  7. Aciex Therapeutics, Inc. · 1 shared drug class
  8. 3D Medicines (Beijing) Co., Ltd. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Sinotau Pharmaceutical Group:

Cite this brief

Drug Landscape (2026). Sinotau Pharmaceutical Group — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/sinotau-pharmaceutical-group. Accessed 2026-05-14.

Related